News & Updates

Treatment with tiotropium appears to reduce the risk of clinically important deterioration (CID) in patients with mild-to-moderate chronic obstructive pulmonary disease (COPD), including those with fewer respiratory symptoms, according to a study.

Sacituzumab govitecan improved progression-free survival (PFS) and overall survival (OS) in Asian patients with HR+/HER2– metastatic breast cancer (mBC) compared with the treatment of physician’s choice (TPC*), according to the EVER-132-002 study presented at ESMO Asia 2023.

It is safe to use long-term growth hormone (GH) therapy in patients with decompensated cirrhosis (DC), suggests a study, noting improvements in malnutrition and even quality of life (QoL). However, 12-month survival does not seem to improve.

More and more patients in the US are being initiated on immunotherapy within 1 month of death, reflecting the rise in use of immunotherapy overall, according to a study.

At the 27th Congress of the Asian Pacific Society of Respirology (APSR) 2023, a Pfizer-sponsored symposium addressed the evolving challenges of COVID-19, particularly for patients with pre-existing respiratory conditions. Chaired by Dr Chan Kwok Wai Adrian, a renowned respiratory physician and intensivist from Mount Elizabeth Novena Hospital, Singapore, and featuring insights from Professor Yang Kuang-Yao of National Yang Ming Chiao Tung University, Taipei, Taiwan, the symposium focused on the disease’s impact, treatment guidelines, regional management strategies, and the role of nirmatrelvir/ritonavir, a new oral combination pill, in the treatment of COVID-19.